Abstract: The present disclosure relates to a technical field of solar cells, and more particularly to an independently-driven film separation mechanism. The separation mechanism includes a mounting platform. A plurality of first suction components for sucking the bottom surfaces of wafers respectively are provided on one side of the mounting platform. Each of the first suction components is corresponding to one of the wafers. The mounting platform is provided with a plurality of second suction components for sucking films respectively, each of the films is provided on a top surface of the corresponding wafer. The first suction components and the second suction components are provided in a one to one correspondence, and a suction direction of each of the plurality of first suction components and a suction direction of each of the plurality of second suction components are opposite.

Abstract: The present disclosure relates to the technical field of solar cells, and more particularly to a film drawing device and method. The film drawing device includes a fixing component and a moving component. The fixing component includes a first fixing plate and a second fixing plate. The first fixing plate and the second fixing plate are opposite to each other and are configured to fix two ends of a film respectively. The moving component is connected to the first fixing, plate and/or the second fixing plate to drive the first fixing plate and/or the second fixing plate to move so as to draw the film. The film drawing device can draw the film. Finally, the entire surface of the film is smooth without folds, precise positioning is facilitated, and the problem of folds formed after bonding is solved.

Abstract: A priming mechanism for operating an automatic injection apparatus to ensure medication contents are properly delivered prior to a needled syringe of the apparatus being injected. The priming mechanism includes a push rod to move plunger(s) within the syringe; a releasable support including bendable supporting arms, which limiting motion of the syringe relative to an upper housing body before and during priming; and a recess element inside the lower housing body to release said bendable arm to allow motion of the syringe relative to the upper housing body in distal direction after priming. In one form, the priming mechanism is used for removing air bubble before injection to ensure delivering correct dose. In another form, the priming mechanism is used to mix different contents in a dual chamber syringe before injection.

Abstract: The present disclosure relates to a wafer positioning and loading system, which includes a picking mechanism, a visual positioning system, a feeding mechanism, and an alignment platform system including a plurality of sub-alignment platforms. The picking mechanism includes an X-direction picking manipulator and a YZ-direction conveying unit, a plurality of first vacuum chucks arranged at intervals for sucking up wafers is disposed on the X-direction picking manipulator, the plurality of first vacuum chucks corresponds one-to-one to the plurality of sub-alignment platforms; the visual positioning system is arranged above the alignment platform system for obtaining the position of the wafers; each the sub-alignment platform adjusts the positions of the wafers according to the positions of the wafers obtained, so that they are coincident with the preset reference position; the feeding mechanism is used for conveying the plurality of wafers adjusted on the plurality of sub-alignment platforms to the destination.

Abstract: In one aspect, a pen needle assembly is provided herein which includes a hub, and a needle fixed to the hub, the needle having proximal and distal ends with a lumen extending therebetween. The needle extends distally from the hub to define an exposed length between the distal end of the needle and the hub in the range of about 5.0 to 9.0 mm. The hub defines a post formed about the needle, the post having a distally-facing first skin engaging surface. The exposed length of the needle extends distally from the first skin engaging surface. The hub also defines a distally-facing second skin engaging surface which at least partially circumscribes the first skin engaging surface. The second skin engaging surface being located proximally of the first skin engaging surface. Advantageously, a pen needle assembly is provided having two skin engaging surfaces which provide stability in achieving subcutaneous injections.

Abstract: The present invention provides a composite intelligent biological phototherapy device including a base structure, a plurality of white light fluorescent tubes arranged side by side on the base structure, a plurality of LEDs disposed between the white light fluorescent tubes, a housing having an opening and configured to accommodate the base structure and the white light fluorescent tubes and the LEDs thereon, a light-transmittable plate disposed on the housing corresponding to the opening, and an control module configured to respectively control the white light fluorescent tubes and the LEDs. The base structure includes a plurality of sections, and each of the sections has a first surface facing the light-transmittable plate. The white light fluorescent tubes and the LEDs are provided on the first surfaces, and the sections are bent relative to each other so an angle between the first surfaces of adjacent sections is less than 180 degrees.

Abstract: Compounds and methods for treating diseases or conditions affected by the activity or expression of genes/proteins related to human GH, GHR, STAT5, SOCS, IGF-1, insulin are provided. Monoclonal antibodies for treating diseases or conditions related to growth hormone and growth hormone receptor activity are also provided.

Abstract: The present disclosure provides a full duplex communication method implemented by a Radio Base Station (RBS) supporting Time Division Duplex (TDD) scheme and the associated RBS. The method comprises configuring a first logic cell and a second logic cell for the RBS by specifying a first downlink/uplink (DL/UL) configuration corresponding to the first logic cell and a second, different DL/UL configuration corresponding to the second logic cell.

Abstract: An injection device is provided herein comprising a container body for holding medication content having a distal end and a proximal end, the container body providing an outward flange at the distal end and a ledge at the proximal end; a piston placed at the proximal end of the container body for sealing and displacing medication content; a push rod placed inside the container body for moving the piston distally; and a connector providing an orifice for medication content delivery, placed at said distal end of said container body. The orifice in the connector provides medication content injection fluid pathway. With modification of the fundamental structure, a number of innovative device designs are created.

Abstract: A test device for testing a first contact lens classified as a specific type of contact lens is disclosed. The test device includes a light emitting unit and a detection unit. The light emitting unit emits a first incident light to the first contact lens to generate a first reflected light having a first light intensity, and the detection unit receives the first reflected light, in response to the first light intensity generates a first light intensity value, and implements a specific water content algorithm based on the first light intensity value to estimate an actual water content associated with the first contact lens, wherein the specific water content algorithm is constructed based on a water content reference data associated with the specific type of contact lens and a corresponding light intensity measurement data associated with the water content reference data.

Abstract: The present invention relates to a new method for successfully inducing the mutation of cell chemokine receptor CCR5 gene into CCR5?32 deletion gene by using the CRISPR-Cas9 genome editing technique. CCR5 is an important co-receptor for entry of Human Immunodeficiency Virus (HIV) into human host cells. CCR5?32 deletion is a 32-bp deletion in CCR5 coding region, which results in change and premature termination in the sequence following the 185th amino acid. Biallelic homozygous deletion of CCR5?32 is naturally resistant to HIV infection, i.e., the people carrying this mutation can't be infected by HIV. The present invention uses both lentiviral packaging system and the CRISPR technique to induce CCR5?32 deletion. Due to the characteristics of a wide range of lentivirus infection, the invention can be applied to cells such as bone marrow stem cells and CD4+ T cells and can be expected to be the therapeutic drug for HIV/AIDS infection or other diseases.

Abstract: A drug delivery device includes a housing component having an interior space and an exterior surface, an injection needle having a retracted state wherein the needle is hosted inside of the interior space and a deployed state wherein a pointed end of the needle projects beyond the exterior surface of the housing component, a needle drive mechanism coupled to the needle to move the needle between the retracted and deployed states, and a drug container disposed within the interior space. The drug container is pre-filled with sterile liquid drug and to be in fluid communication with the needle. The sterile liquid drug herein might be solution, suspension, emulation or other forms in fluid state. The drug delivery device also includes a microcontroller coupled to the needle drive mechanism. The microcontroller is configured to control the needle drive mechanism to move the needle between the retracted state and the deployed state. Further, the delivery device is wearable, disposable, and single-use.

Abstract: A drug delivery device is provided herein which includes a tubular body defining an opening. A drug cartridge is also provided having a distal end larger in diameter than the opening. With the drug cartridge being inserted into the tubular body in a use position, the distal end of the drug cartridge is located at least partially externally of the tubular body. The medical pen injector of the subject invention further includes an adaptor engageable with the body. The adaptor encompasses the distal end of the drug cartridge with the drug cartridge being in the use position. The adaptor includes features for mounting a needle assembly thereto. Advantageously, with the subject invention, a drug cartridge having a large distal end may be accommodated with a drug delivery device, e.g., a pen injector type device.

Abstract: A system for online monitoring powder-based 3D printing processes and method thereof are disclosed. A uniform light source having a single wavelength provided by the system is irradiated onto the powder layer before and after applied with glue. Intensities of such reflected images are obtained and subtracted from each other in an image process procedure. A difference obtained through the subtraction is compared with an original 3D model in a computer. If any defect is found such as being larger than a threshold value, the powder-based 3D printing processes will be terminated. Therefore, the technical effects of online printing processes monitoring, time saving and printing resources saving will be achieved.

Abstract: A pre-filled syringe for sterile medication fluid injection includes a syringe barrel with rotationally symmetric cylindrical bore, having a distal end and a proximal end; a syringe piston with rotationally symmetric external shape; a backstop mounted at the proximal end of the syringe barrel with an opening that is rotationally asymmetric about the axis through the syringe barrel; a push rod to move the syringe piston inside the syringe barrel, wherein at least one portion of the push rod is rotationally asymmetric about the axis through the syringe barrel, and upon rotation, the rotationally asymmetric portion of the push rod is aligned with the rotationally asymmetric opening of the backstop; and a seal component to cover the distal end of the syringe barrel.

Abstract: A fasting mimicking diet package providing daily meal portions for a predetermined number of days is provided. The fasting mimicking diet package includes a kale cracker composition, a first vegetable broth composition, a mushroom soup composition, a tomato soup composition, a quinoa-containing minestrone soup composition, a bean-containing minestrone soup composition, and a pumpkin soup composition. Characteristically, the daily meal portions are packaged into meal servings or into a total daily serving to be divided into meals.

Abstract: The invention relates to a method of determining characteristics of orifices (O1, . . . , O9) to be made through a plate (2) positioned in a circuit (10) across the fluid passage. Said method comprises defining fluid data, the number of orifices, and for each orifice a control segment or area. The fluid flow rate through each orifice of the perforated plate is calculated, and for each orifice, the flow rate density is calculated by dividing said fluid flow rate by the associated control segment length or control area. The optimized or non-optimized nature of the orifice characteristic is determined by comparing said flow rate density with the mean flow rate density. If the difference in absolute value lies within a predetermined range of values, then the orifice characteristics are considered as being optimized. Otherwise at least one characteristic of at least some of the orifices is modified.

Abstract: The method set out herein involves conducting clinical trial to develop parenteral therapeutic product with drug delivery device. The method comprises conducting a dose-finding clinical study using a variable dose drug delivery device to evaluate multiple clinical doses, wherein the variable dose drug delivery device is automatic, portable and for user self-administration. During the dose-finding clinical study, both the performance of the drug and the performance of the variable dose drug delivery device are evaluated.

Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.